Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating …

cyclophosphamide
vincristine
anticonvulsants
neutrophil count
immunohistochemistry
  • 217 views
  • 14 Oct, 2022
  • 128 locations
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial (ImproveCodel)

improved outcome as is the addition of chemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) to the partial brain radiotherapy (RT). However, the exact timing of postsurgical therapy

vincristine
MRI
IDH2
lomustine
immunohistochemistry
  • 0 views
  • 19 Oct, 2022
  • 17 locations
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with high-risk molecular biomarkers who still have detectable minimal residual disease(MRD) pre-HSCT were at very high …

cell transplantation
cyclophosphamide
busulfan
acute leukemia
minimal residual disease
  • 2 views
  • 01 Mar, 2022
  • 1 location
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with relapse or refractory AL were at very high risk of relapse post allo-HSCT, with cumulative …

cell transplantation
cyclophosphamide
busulfan
acute leukemia
remission
  • 1 views
  • 09 Feb, 2022
  • 1 location